[6] SGLT2 is located in the early proximal tubule, and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney glomerulus.

Gliflozins enhance glycemic control as well as reduce body weight and systolic and diastolic blood pressure.

[10][11] Other side effects of gliflozins include increased risk of Fournier gangrene[12] and of (generally mild) genital infections such as candidal vulvovaginitis.

[14] Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with significant long-term reductions in mortality risk for patients with pulmonary arterial hypertension (PAH), according to an observational cohort study.

[15] The study revealed that after one year, 8.1% of PAH patients prescribed SGLT2 inhibitors had died, compared to 15.5% of those who did not take the medication.